<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424306</url>
  </required_header>
  <id_info>
    <org_study_id>NHLBI R21 HL108257</org_study_id>
    <secondary_id>R21HL108257</secondary_id>
    <nct_id>NCT01424306</nct_id>
  </id_info>
  <brief_title>Diet and Systemic Inflammation</brief_title>
  <acronym>DASI</acronym>
  <official_title>Diet and Systemic Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with chronic low-grade inflammation have a higher risk for certain diseases such as
      cardiovascular disease or type 2 diabetes. While it is known that obese people are more
      likely to show signs of low-grade inflammation than lean individuals, it is unclear what
      causes this inflammation. In the proposed study, the investigators will examine whether the
      sugar fructose, when consumed in a sweetened beverage, triggers low-grade inflammation in
      healthy men and women compared with other caloric sweeteners.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this proposal is to investigate whether fructose-sweetened beverages trigger
      low-grade systemic inflammation in healthy men and women. Low-grade systemic inflammation,
      specifically elevated plasma concentrations of C-reactive protein (CRP), is a risk factor for
      cardiovascular disease (CVD). While it is known that obesity is associated with inflammation,
      the causes of low-grade inflammation in humans are not well understood. In a pilot study, the
      consumption of large amounts of fructose-, but not glucose- or aspartame-sweetened beverages
      potently induced low-grade inflammation in healthy, lean, young men and women in as little as
      8 days. The investigators propose to extend these findings by (a) enrolling a greater number
      of subjects, (b) enrolling obese as well as non-obese subjects, and (c) including a beverage
      that is sweetened with high fructose corn syrup (HFCS). HFCS is one of the primary sugars
      consumed in the United States, and a major source of dietary fructose. Our primary specific
      aim is to assess whether the consumption of fructose- or HFCS-sweetened beverages promotes
      systemic low-grade inflammation, as measured by plasma concentrations of CRP and IL-6. The
      investigators hypothesize that plasma CRP and IL-6 concentrations will be elevated after
      consumption of fructose-containing beverages (fructose and HFCS) when compared to a
      glucose-sweetened beverage. Our secondary specific aim is to assess whether the consumption
      of fructose- or HFCS-sweetened beverages lowers plasma adiponectin concentrations.
      Specifically, the investigators hypothesize that total and high molecular weight
      (HMW)-adiponectin concentrations in fasting plasma will be lower after subjects have consumed
      the fructose- or HFCS-sweetened beverages, compared to a glucose-sweetened beverage.

      The investigators will recruit 12 overweight/obese (BMI between 25.0 and 40 kg/m2) and 12
      normal weight (BMI between 20 and 24.9 kg/m2) men and women who are free of chronic
      inflammatory or metabolic disease. In a double-blind, randomized cross-over design, each
      subject will complete three 8-day standardized dietary periods that will differ only in the
      type of sweetened beverage administered. Specifically, subjects will be asked to drink four
      servings of a beverage each day that is sweetened with glucose, fructose, or HFCS (55%
      fructose, 45% glucose). All solid food will be provided for each of the three 8-day diet
      periods, and will be consumed ad libitum. Following each dietary period, the investigators
      will collect fasting blood to measure markers of systemic inflammation and plasma
      concentrations of total and HMW-adiponectin. We will also assess changes in adipose tissue
      inflammation and intestinal permeability as potential mechanisms by which fructose-sweetened
      beverages may trigger systemic inflammation. This study has the potential to identify a
      dietary trigger of low-grade inflammation, a likely contributor to CVD and metabolic
      diseases. The public health impact of this project might be considerable given that the
      consumption of fructose in the population is pervasive, and is modifiable on an individual as
      well as a population level.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Plasma C-reactive Protein</measure>
    <time_frame>Beginning (day 1) and end (day 9) of each diet period.</time_frame>
    <description>The concentration of C-reactive protein in fasting plasma will be measured by high-sensitivity assay at the beginning (day 1) and end (day 9) of each 8-day dietary period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Plasma Interleukin-6 on Day 9 of Each Diet Period</measure>
    <time_frame>End (day 9) of each diet period</time_frame>
    <description>The concentration of interleukin-6 in fasting plasma will be measured by high-sensitivity enzyme-linked immunosorbent assay at the end (day 9) of each 8-day dietary period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Adiponectin</measure>
    <time_frame>End (day 9) of each diet period.</time_frame>
    <description>The concentration of adiponectin in fasting plasma will be measured by enzyme-linked immunosorbent assay at the end (day 9) of each 8-day dietary period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Calorie Intake</measure>
    <time_frame>The mean daily calorie intake during each of the 8-day diet periods will be calculated.</time_frame>
    <description>Mean daily calorie intake will be assessed during each of the three 8-day diet periods. All foods will be provided to the subjects in excess of what they are estimated to require, and calorie intake will be assessed by subtracting returned foods from foods administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal Permeability, as Assessed by the 5-hour Urinary Lactulose/Mannitol Test</measure>
    <time_frame>End (day 9) of each diet period.</time_frame>
    <description>Intestinal permeability will be assessed on day 9 of each diet period by administering a beverage containing 2 g of mannitol and 5 g of lactulose followed by collecting urine for 5 hours afterwards. Recovery of mannitol and lactulose in urine will be measured by gas chromatography, and will be indicative of the degree of intestinal permeability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Zonulin Concentrations</measure>
    <time_frame>End (day 9) of each diet period.</time_frame>
    <description>Zonulin concentrations will be measured by enzyme-linked immunosorbent assay in fasting plasma collected on day 9 of each diet period. Plasma zonulin is a marker of intestinal permeability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Lipopolysaccharide-binding Protein (LBP)</measure>
    <time_frame>End (day 9) of each diet period.</time_frame>
    <description>Lipopolysaccharide-binding protein (LBP) will be measured by enzyme-linked immunosorbent assay in fasting plasma collected on day 9 of each diet period. LBP is an acute phase protein secreted by the liver in response to endotoxin (lipopolysaccharide) exposure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose Tissue Inflammation - Tissue Expression of TNF-alpha mRNA</measure>
    <time_frame>End (day 9) of each diet period.</time_frame>
    <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of TNF-alpha mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose Tissue Inflammation - Tissue Expression of IL-1beta mRNA</measure>
    <time_frame>End (day 9) of each diet period.</time_frame>
    <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of IL-1beta mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose Tissue Inflammation - Tissue Expression of IL-6 mRNA</measure>
    <time_frame>End (day 9) of each diet period.</time_frame>
    <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of IL-6 mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose Tissue Inflammation - Tissue Expression of IL-10 mRNA</measure>
    <time_frame>End (day 9) of each diet period.</time_frame>
    <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of IL-10 mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose Tissue Inflammation - Tissue Expression of CCL2 mRNA</measure>
    <time_frame>End (day 9) of each diet period.</time_frame>
    <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of CCL2 mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose Tissue Inflammation - Tissue Expression of IFN-gamma mRNA</measure>
    <time_frame>End (day 9) of each diet period.</time_frame>
    <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of IFN-gamma mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Low-grade Chronic Inflammation</condition>
  <condition>Intestinal Permeability</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Fructose-sweetened beverages</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose-sweetened beverages</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-fructose corn syrup-sweetened beverages</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fructose-sweetened beverages</intervention_name>
    <description>In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days. The amount of fructose consumed will be 25% of the subject's estimated daily calorie requirement.</description>
    <arm_group_label>Fructose-sweetened beverages</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose-sweetened beverages</intervention_name>
    <description>In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days. The amount of glucose consumed will be 25% of the subject's estimated daily calorie requirement.</description>
    <arm_group_label>Glucose-sweetened beverages</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High-fructose corn syrup-sweetened beverages</intervention_name>
    <description>In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days. The amount of high-fructose corn syrup consumed will be 25% of the subject's estimated daily calorie requirement.</description>
    <arm_group_label>High-fructose corn syrup-sweetened beverages</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-65 years;

          -  BMI 20-40 kg/m2;

          -  Weight stable to within 10 pounds for 6 months prior to entering the study, and at
             their lifetime maximum weight (or within 30 pounds of it; excluding pregnancy);

          -  Ability to be admitted for ~30 minutes on three occasions, and ~6 hours on three
             occasions to the FHCRC Prevention Center;

          -  Ability to provide informed written consent;

          -  Willingness to consume only food and beverages provided by the Human Nutrition
             Laboratory of the FHCRC Prevention Center for three periods of 8 days each.

        Exclusion Criteria:

          -  Presence or history of chronic inflammatory, autoimmune or metabolic diseases;

          -  Presence of phenylketonuria, hereditary fructose intolerance, fructose malabsorption,
             or malabsorption syndromes;

          -  Abuse of alcohol (&gt;2 drinks per day), smoking, or use of recreational drugs;

          -  Current or recent (within three months) intake of medications likely to interfere with
             study endpoints (insulin, antidiabetics, Î²-blockers, anabolic steroids,
             glucocorticosteroids, daily high-dose non-steroidal anti-inflammatory drugs, warfarin,
             antibiotics, probiotics);

          -  Presence of anemia, recent (within 2 months) history of anemia;

          -  Anyone not willing or able to eat the provided food;

          -  Current or recent (within 12 months) pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Kratz, MS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ajcn.nutrition.org/content/102/6/1373.long</url>
    <description>Full text article</description>
  </link>
  <link>
    <url>http://ajcn.nutrition.org/content/104/2/306.long</url>
    <description>Full text article</description>
  </link>
  <reference>
    <citation>Kuzma JN, Cromer G, Hagman DK, Breymeyer KL, Roth CL, Foster-Schubert KE, Holte SE, Callahan HS, Weigle DS, Kratz M. No difference in ad libitum energy intake in healthy men and women consuming beverages sweetened with fructose, glucose, or high-fructose corn syrup: a randomized trial. Am J Clin Nutr. 2015 Dec;102(6):1373-80. doi: 10.3945/ajcn.115.116368. Epub 2015 Nov 4.</citation>
    <PMID>26537945</PMID>
  </reference>
  <reference>
    <citation>Kuzma JN, Cromer G, Hagman DK, Breymeyer KL, Roth CL, Foster-Schubert KE, Holte SE, Weigle DS, Kratz M. No differential effect of beverages sweetened with fructose, high-fructose corn syrup, or glucose on systemic or adipose tissue inflammation in normal-weight to obese adults: a randomized controlled trial. Am J Clin Nutr. 2016 Aug;104(2):306-14. doi: 10.3945/ajcn.115.129650. Epub 2016 Jun 29.</citation>
    <PMID>27357093</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <results_first_submitted>April 19, 2017</results_first_submitted>
  <results_first_submitted_qc>July 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2017</results_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Mario Kratz</investigator_full_name>
    <investigator_title>Associate Member</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Intestinal permeability</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Obesity</keyword>
  <keyword>Sweetened beverages</keyword>
  <keyword>Sugar</keyword>
  <keyword>Fructose</keyword>
  <keyword>Glucose</keyword>
  <keyword>High-fructose corn syrup</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>63 volunteers who responded to newspaper advertisements and fliers posted in the Seattle area were screened for eligibility between December 2011 and December 2013.</recruitment_details>
      <pre_assignment_details>Of those 63 volunteers screened, 38 did not meet inclusion criteria and 0 declined to participate. 25 subjects randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fructose - Glucose - HFCS</title>
          <description>Subjects treated in the order fructose-sweetened beverage - wash out - glucose-sweetened beverage- wash out - HFCS-sweetened beverage
Treatments each lasted 8 days and were separated by a 20-day washout.</description>
        </group>
        <group group_id="P2">
          <title>Fructose - HFCS - Glucose</title>
          <description>Subjects treated in the order fructose-sweetened beverage - wash out - HFCS-sweetened beverage- wash out - glucose-sweetened beverage
Treatments each lasted 8 days and were separated by a 20-day washout.</description>
        </group>
        <group group_id="P3">
          <title>HFCS - Fructose - Glucose</title>
          <description>Subjects treated in the order HFCS-sweetened beverage - wash out - fructose-sweetened beverage- wash out - glucose-sweetened beverage
Treatments each lasted 8 days and were separated by a 20-day washout.</description>
        </group>
        <group group_id="P4">
          <title>HFCS - Glucose - Fructose</title>
          <description>Subjects treated in the order HFCS-sweetened beverage - wash out - glucose-sweetened beverage- wash out - fructose-sweetened beverage
Treatments each lasted 8 days and were separated by a 20-day washout.</description>
        </group>
        <group group_id="P5">
          <title>Glucose - Fructose - HFCS</title>
          <description>Subjects treated in the order glucose-sweetened beverage - wash out - fructose-sweetened beverage- wash out - HFCS-sweetened beverage
Treatments each lasted 8 days and were separated by a 20-day washout.</description>
        </group>
        <group group_id="P6">
          <title>Glucose - HFCS - Fructose</title>
          <description>Subjects treated in the order glucose-sweetened beverage - wash out - HFCS-sweetened beverage- wash out - fructose-sweetened beverage
Treatments each lasted 8 days and were separated by a 20-day washout.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only results of 24 subjects who completed study 'per protocol' are reported here</population>
      <group_list>
        <group group_id="B1">
          <title>Study Subjects</title>
          <description>All six treatment orders combined</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physical activity</title>
          <units>MET-hr/wk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.7" spread="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated total calorie requirement</title>
          <units>kcal/d</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2560" spread="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fasting Plasma C-reactive Protein</title>
        <description>The concentration of C-reactive protein in fasting plasma will be measured by high-sensitivity assay at the beginning (day 1) and end (day 9) of each 8-day dietary period.</description>
        <time_frame>Beginning (day 1) and end (day 9) of each diet period.</time_frame>
        <population>All completed participants combined in per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm - Day 1</title>
            <description>CRP measured on day 1 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Fructose Arm - Day 9</title>
            <description>CRP measured on day 9 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>Glucose Arm - Day 1</title>
            <description>CRP measured on day 1 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O4">
            <title>Glucose Arm - Day 9</title>
            <description>CRP measured on day 9 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O5">
            <title>HFCS Arm - Day 1</title>
            <description>CRP measured on day 1 of HFCS-sweetened beverage intervention period</description>
          </group>
          <group group_id="O6">
            <title>HFCS Arm - Day 9</title>
            <description>CRP measured on day 9 of HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma C-reactive Protein</title>
          <description>The concentration of C-reactive protein in fasting plasma will be measured by high-sensitivity assay at the beginning (day 1) and end (day 9) of each 8-day dietary period.</description>
          <population>All completed participants combined in per protocol analysis</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" lower_limit="0.45" upper_limit="2.35"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.48" upper_limit="2.10"/>
                    <measurement group_id="O3" value="1.67" lower_limit="0.36" upper_limit="2.91"/>
                    <measurement group_id="O4" value="1.09" lower_limit="0.38" upper_limit="3.04"/>
                    <measurement group_id="O5" value="1.18" lower_limit="0.38" upper_limit="2.49"/>
                    <measurement group_id="O6" value="0.84" lower_limit="0.49" upper_limit="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>RM-ANOVA</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.403</p_value>
            <p_value_desc>P value for the time x diet interaction reflects overall comparison of 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Plasma Interleukin-6 on Day 9 of Each Diet Period</title>
        <description>The concentration of interleukin-6 in fasting plasma will be measured by high-sensitivity enzyme-linked immunosorbent assay at the end (day 9) of each 8-day dietary period.</description>
        <time_frame>End (day 9) of each diet period</time_frame>
        <population>All completed participants combined in per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm - Day 9</title>
            <description>IL-6 measured on day 9 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Glucose Arm - Day 9</title>
            <description>IL-6 measured on day 9 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>HFCS Arm - Day 9</title>
            <description>IL-6 measured on day 9 of HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Interleukin-6 on Day 9 of Each Diet Period</title>
          <description>The concentration of interleukin-6 in fasting plasma will be measured by high-sensitivity enzyme-linked immunosorbent assay at the end (day 9) of each 8-day dietary period.</description>
          <population>All completed participants combined in per protocol analysis</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.62" upper_limit="1.90"/>
                    <measurement group_id="O2" value="1.14" lower_limit="0.61" upper_limit="1.95"/>
                    <measurement group_id="O3" value="0.96" lower_limit="0.61" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>RM-ANOVA</non_inferiority_desc>
            <p_value>0.933</p_value>
            <p_value_desc>P-diet: reflects an overall comparison of the 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Adiponectin</title>
        <description>The concentration of adiponectin in fasting plasma will be measured by enzyme-linked immunosorbent assay at the end (day 9) of each 8-day dietary period.</description>
        <time_frame>End (day 9) of each diet period.</time_frame>
        <population>All completed participants combined in per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm - Day 9</title>
            <description>Adiponectin measured on day 9 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Glucose Arm - Day 9</title>
            <description>Adiponectin measured on day 9 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>HFCS Arm - Day 9</title>
            <description>Adiponectin measured on day 9 of HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Adiponectin</title>
          <description>The concentration of adiponectin in fasting plasma will be measured by enzyme-linked immunosorbent assay at the end (day 9) of each 8-day dietary period.</description>
          <population>All completed participants combined in per protocol analysis</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4635" spread="2545"/>
                    <measurement group_id="O2" value="4353" spread="2198"/>
                    <measurement group_id="O3" value="4514" spread="2195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>RM-ANOVA</non_inferiority_desc>
            <p_value>0.196</p_value>
            <p_value_desc>P-diet: reflects an overall comparison of the 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Calorie Intake</title>
        <description>Mean daily calorie intake will be assessed during each of the three 8-day diet periods. All foods will be provided to the subjects in excess of what they are estimated to require, and calorie intake will be assessed by subtracting returned foods from foods administered.</description>
        <time_frame>The mean daily calorie intake during each of the 8-day diet periods will be calculated.</time_frame>
        <population>All completed participants combined in per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm</title>
            <description>Average total energy consumed each day during the fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Glucose Arm</title>
            <description>Average total energy consumed each day during the glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>HFCS Arm</title>
            <description>Average total energy consumed each day during the HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Calorie Intake</title>
          <description>Mean daily calorie intake will be assessed during each of the three 8-day diet periods. All foods will be provided to the subjects in excess of what they are estimated to require, and calorie intake will be assessed by subtracting returned foods from foods administered.</description>
          <population>All completed participants combined in per protocol analysis</population>
          <units>kcal/d</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2970" spread="482"/>
                    <measurement group_id="O2" value="2940" spread="460"/>
                    <measurement group_id="O3" value="2950" spread="535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>RM-ANOVA</non_inferiority_desc>
            <p_value>0.880</p_value>
            <p_value_desc>Reflects an overall comparison of the 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intestinal Permeability, as Assessed by the 5-hour Urinary Lactulose/Mannitol Test</title>
        <description>Intestinal permeability will be assessed on day 9 of each diet period by administering a beverage containing 2 g of mannitol and 5 g of lactulose followed by collecting urine for 5 hours afterwards. Recovery of mannitol and lactulose in urine will be measured by gas chromatography, and will be indicative of the degree of intestinal permeability.</description>
        <time_frame>End (day 9) of each diet period.</time_frame>
        <population>All completed participants combined in per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm - Day 9</title>
            <description>Lactulose:Mannitol ratio measured on day 9 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Glucose Arm - Day 9</title>
            <description>Lactulose:Mannitol ratio measured on day 9 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>HFCS Arm - Day 9</title>
            <description>Lactulose:Mannitol ratio measured on day 9 of HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Intestinal Permeability, as Assessed by the 5-hour Urinary Lactulose/Mannitol Test</title>
          <description>Intestinal permeability will be assessed on day 9 of each diet period by administering a beverage containing 2 g of mannitol and 5 g of lactulose followed by collecting urine for 5 hours afterwards. Recovery of mannitol and lactulose in urine will be measured by gas chromatography, and will be indicative of the degree of intestinal permeability.</description>
          <population>All completed participants combined in per protocol analysis</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047" lower_limit="0.031" upper_limit="0.054"/>
                    <measurement group_id="O2" value="0.043" lower_limit="0.031" upper_limit=".048"/>
                    <measurement group_id="O3" value="0.031" lower_limit="0.026" upper_limit="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>RM-ANOVA</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value reflects an overall comparison of the 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>Repeated measures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Zonulin Concentrations</title>
        <description>Zonulin concentrations will be measured by enzyme-linked immunosorbent assay in fasting plasma collected on day 9 of each diet period. Plasma zonulin is a marker of intestinal permeability.</description>
        <time_frame>End (day 9) of each diet period.</time_frame>
        <population>All completed participants combined in per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm - Day 9</title>
            <description>Zonulin measured on day 9 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Glucose Arm - Day 9</title>
            <description>Zonulin measured on day 9 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>HFCS Arm - Day 9</title>
            <description>Zonulin measured on day 9 of HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Zonulin Concentrations</title>
          <description>Zonulin concentrations will be measured by enzyme-linked immunosorbent assay in fasting plasma collected on day 9 of each diet period. Plasma zonulin is a marker of intestinal permeability.</description>
          <population>All completed participants combined in per protocol analysis</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.78" spread="1.54"/>
                    <measurement group_id="O2" value="12.69" spread="1.70"/>
                    <measurement group_id="O3" value="12.92" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>RM-ANOVA</non_inferiority_desc>
            <p_value>0.366</p_value>
            <p_value_desc>P-value reflects an overall comparison of the 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Lipopolysaccharide-binding Protein (LBP)</title>
        <description>Lipopolysaccharide-binding protein (LBP) will be measured by enzyme-linked immunosorbent assay in fasting plasma collected on day 9 of each diet period. LBP is an acute phase protein secreted by the liver in response to endotoxin (lipopolysaccharide) exposure.</description>
        <time_frame>End (day 9) of each diet period.</time_frame>
        <population>All completed participants combined for protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm - Day 9</title>
            <description>LBP measured on day 9 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Glucose Arm - Day 9</title>
            <description>LBP measured on day 9 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>HFCS Arm - Day 9</title>
            <description>LBP measured on day 9 of HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Lipopolysaccharide-binding Protein (LBP)</title>
          <description>Lipopolysaccharide-binding protein (LBP) will be measured by enzyme-linked immunosorbent assay in fasting plasma collected on day 9 of each diet period. LBP is an acute phase protein secreted by the liver in response to endotoxin (lipopolysaccharide) exposure.</description>
          <population>All completed participants combined for protocol analysis</population>
          <units>ug/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" lower_limit="19.8" upper_limit="34.2"/>
                    <measurement group_id="O2" value="26.1" lower_limit="21.7" upper_limit="40.0"/>
                    <measurement group_id="O3" value="29.8" lower_limit="21.5" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>RM-ANOVA</non_inferiority_desc>
            <p_value>0.387</p_value>
            <p_value_desc>P-value reflects overall comparison of the 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adipose Tissue Inflammation - Tissue Expression of TNF-alpha mRNA</title>
        <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of TNF-alpha mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
        <time_frame>End (day 9) of each diet period.</time_frame>
        <population>A subset of the study population opted to undergo voluntary adipose tissue biopsy</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm - Day 9</title>
            <description>Gene expression measured on day 9 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Glucose Arm - Day 9</title>
            <description>Gene expression measured on day 9 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>HFCS Arm - Day 9</title>
            <description>Gene expression measured on day 9 of HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Adipose Tissue Inflammation - Tissue Expression of TNF-alpha mRNA</title>
          <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of TNF-alpha mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
          <population>A subset of the study population opted to undergo voluntary adipose tissue biopsy</population>
          <units>copy number/ng total RNA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.58"/>
                    <measurement group_id="O2" value="1.44" spread="0.89"/>
                    <measurement group_id="O3" value="1.24" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>RM-ANOVA</non_inferiority_desc>
            <p_value>0.476</p_value>
            <p_value_desc>P-value reflects overall comparison of the 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adipose Tissue Inflammation - Tissue Expression of IL-1beta mRNA</title>
        <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of IL-1beta mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
        <time_frame>End (day 9) of each diet period.</time_frame>
        <population>A subset of the study population opted to undergo voluntary adipose tissue biopsy</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm - Day 9</title>
            <description>Gene expression measured on day 9 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Glucose Arm - Day 9</title>
            <description>Gene expression measured on day 9 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>HFCS Arm - Day 9</title>
            <description>Gene expression measured on day 9 of HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Adipose Tissue Inflammation - Tissue Expression of IL-1beta mRNA</title>
          <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of IL-1beta mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
          <population>A subset of the study population opted to undergo voluntary adipose tissue biopsy</population>
          <units>copy number/ng total RNA</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.26" upper_limit="0.54"/>
                    <measurement group_id="O2" value="0.33" lower_limit="0.25" upper_limit="0.41"/>
                    <measurement group_id="O3" value="0.32" lower_limit="0.27" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>RM-ANOVA</non_inferiority_desc>
            <p_value>0.596</p_value>
            <p_value_desc>P-value reflects overall comparison of the 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adipose Tissue Inflammation - Tissue Expression of IL-6 mRNA</title>
        <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of IL-6 mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
        <time_frame>End (day 9) of each diet period.</time_frame>
        <population>A subset of the study population opted to undergo voluntary adipose tissue biopsy</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm - Day 9</title>
            <description>Gene expression measured on day 9 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Glucose Arm - Day 9</title>
            <description>Gene expression measured on day 9 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>HFCS Arm - Day 9</title>
            <description>Gene expression measured on day 9 of HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Adipose Tissue Inflammation - Tissue Expression of IL-6 mRNA</title>
          <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of IL-6 mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
          <population>A subset of the study population opted to undergo voluntary adipose tissue biopsy</population>
          <units>copy number/ng total RNA</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.35" upper_limit="0.74"/>
                    <measurement group_id="O2" value="0.49" lower_limit="0.37" upper_limit="0.58"/>
                    <measurement group_id="O3" value="0.51" lower_limit="0.38" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>RM-ANOVA</non_inferiority_desc>
            <p_value>0.492</p_value>
            <p_value_desc>P-value reflects overall comparison of the 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adipose Tissue Inflammation - Tissue Expression of IL-10 mRNA</title>
        <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of IL-10 mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
        <time_frame>End (day 9) of each diet period.</time_frame>
        <population>A subset of the study population opted to undergo voluntary adipose tissue biopsy</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm - Day 9</title>
            <description>Gene expression measured on day 9 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Glucose Arm - Day 9</title>
            <description>Gene expression measured on day 9 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>HFCS Arm - Day 9</title>
            <description>Gene expression measured on day 9 of HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Adipose Tissue Inflammation - Tissue Expression of IL-10 mRNA</title>
          <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of IL-10 mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
          <population>A subset of the study population opted to undergo voluntary adipose tissue biopsy</population>
          <units>copy number/ng total RNA</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.34" upper_limit="1.14"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.65" upper_limit="1.19"/>
                    <measurement group_id="O3" value="0.95" lower_limit="0.34" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>RM-ANOVA</non_inferiority_desc>
            <p_value>0.149</p_value>
            <p_value_desc>P-value reflects overall comparison of the 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adipose Tissue Inflammation - Tissue Expression of CCL2 mRNA</title>
        <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of CCL2 mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
        <time_frame>End (day 9) of each diet period.</time_frame>
        <population>A subset of the study population opted to undergo voluntary adipose tissue biopsy</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm - Day 9</title>
            <description>Gene expression measured on day 9 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Glucose Arm - Day 9</title>
            <description>Gene expression measured on day 9 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>HFCS Arm - Day 9</title>
            <description>Gene expression measured on day 9 of HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Adipose Tissue Inflammation - Tissue Expression of CCL2 mRNA</title>
          <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of CCL2 mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
          <population>A subset of the study population opted to undergo voluntary adipose tissue biopsy</population>
          <units>copy number/ng total RNA</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" lower_limit="22.9" upper_limit="47.6"/>
                    <measurement group_id="O2" value="27.2" lower_limit="22.6" upper_limit="33.6"/>
                    <measurement group_id="O3" value="25.3" lower_limit="19.3" upper_limit="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>RM-ANOVA</non_inferiority_desc>
            <p_value>0.056</p_value>
            <p_value_desc>P-value reflects overall comparison of the 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adipose Tissue Inflammation - Tissue Expression of IFN-gamma mRNA</title>
        <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of IFN-gamma mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
        <time_frame>End (day 9) of each diet period.</time_frame>
        <population>A subset of the study population opted to undergo voluntary adipose tissue biopsy</population>
        <group_list>
          <group group_id="O1">
            <title>Fructose Arm - Day 9</title>
            <description>Gene expression measured on day 9 of fructose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O2">
            <title>Glucose Arm - Day 9</title>
            <description>Gene expression measured on day 9 of glucose-sweetened beverage intervention period</description>
          </group>
          <group group_id="O3">
            <title>HFCS Arm - Day 9</title>
            <description>Gene expression measured on day 9 of HFCS-sweetened beverage intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Adipose Tissue Inflammation - Tissue Expression of IFN-gamma mRNA</title>
          <description>A subgroup of the study population will be enrolled into an ancillary study that will aim to assess the effects of consuming fructose- vs. high-fructose corn syrup- vs. glucose-sweetened beverages on adipose tissue inflammation. Adipose tissue inflammation will be assessed by whole adipose tissue gene expression analysis of IFN-gamma mRNA. Abdominal subcutaneous adipose tissue samples will be obtained from subjects enrolled into the ancillary study by needle aspiration biopsy on day 9 of each 8-day dietary period.</description>
          <population>A subset of the study population opted to undergo voluntary adipose tissue biopsy</population>
          <units>copy number/ng total RNA</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="0.15" upper_limit="0.44"/>
                    <measurement group_id="O2" value="0.20" lower_limit="0.15" upper_limit="0.27"/>
                    <measurement group_id="O3" value="0.23" lower_limit="0.17" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>RM-ANOVA</non_inferiority_desc>
            <p_value>0.520</p_value>
            <p_value_desc>P-value reflects overall comparison of the 3 dietary phases by RM-ANOVA</p_value_desc>
            <method>RM-ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fructose Arm</title>
          <description>Powdered fructose mixed with powdered drink flavoring (Lemon)</description>
        </group>
        <group group_id="E2">
          <title>Glucose Arm</title>
          <description>Powdered dextrose mixed with powdered drink flavoring (Lemon) and aspartame to match sweetness</description>
        </group>
        <group group_id="E3">
          <title>HFCS Arm</title>
          <description>HFCS liquid mixed with powdered drink flavoring (Lemon) and aspartame to match sweetness</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal discomfort</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Gastrointestinal discomfort including cramping, bloating, and/or diarrhea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruise from abdominal needle aspiration biospy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mario Kratz</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-7362</phone>
      <email>mkratz@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

